[Direct answer]In the Beijing area, there are three key factors that determine the outcome of disputes over critical illness insurance claims: whether the disease definition complies with the contractual provisions and medical standards (if the diagnosis name does not match the clause, the claim will be reviewed based on the medical classification); whether the restrictions on treatment methods are valid (standard clauses limiting treatment methods are generally not supported); and whether the insurer has fulfilled its obligation to provide clear explanations (disclaimers that are not explained to the insured will not take effect). In the event of clause disputes, the court generally rules in favor of the patient.

I. Problem Background and Typical Scenarios

The typical tug-of-war in critical illness claims settlement: being diagnosed with a critical illness, the insurance company says "the disease state does not meet the provisions of the contract"; the surgical method is different from what is written in the contract, and the claim is blocked; the clause stipulates that "acute myocardial infarction must meet four indicators", and the patient is rejected because he meets three of them; there is a dispute over the distinction between light and severe illness, and the compensation ratio varies by several times. The professional threshold of critical illness insurance clauses is high, and the disputes are the most intense.

II. Key points of dispute

First, the interpretation of the disease definition. Handling conflicts between clause definitions and medical classifications (ICD standards). Second, the effectiveness of treatment methods clauses. Review of standard clauses restricting surgical methods and treatment approaches. Third, clarifying the obligation to provide clear explanations. Providing guidance on exemption clauses and claims settlement standards. Fourth, distinguishing between mild and severe diseases. Corresponding stages, classifications, and payout structures.

III. Professional analysis by Henglue Law Firm

The adjudication experience of critical illness insurance claims disputes is illustrated by two public precedents: - In a final judgment of the Beijing Financial Court, a 6-year-old boy was diagnosed with Wilson's disease, and the insurance company denied coverage on the grounds that "he did not use the specified chelating agent for treatment." The court confirmed that the choice of treatment method is not necessarily related to the severity of the disease, and insurance contracts cannot impose conditions on insureds' right to choose reasonable treatment options. Where standard clauses create unreasonable barriers to claims settlement that violate general medical standards, Article 19 of the Insurance Law prohibits their enforcement. The court ultimately awarded the insured 400,000 yuan in insurance compensation and waived subsequent premium payments. - In a case from Pingjiang County Court in Hunan, Ms. Li was denied critical illness insurance coverage for acute myeloid leukemia, with the insurer citing "failure to disclose prenatal anemia during the application process." The court ruled that the insurer failed to prove the existence of moderate-to-severe anemia at the time of application or its causal link to the leukemia, rendering the termination of the contract invalid. According to the ICD-10 and ICD-O-3 medical classification standards, acute myeloid leukemia falls under the coverage category of "malignant tumors - severe." The court awarded the insured over 99,000 yuan in critical illness insurance compensation. Three key adjudication principles established by these cases: 1. Strict review of treatment method clauses - Medical advances have led to evolving treatment methods, but clauses restricting specific drugs or surgical procedures violate insureds' right to reasonable medical choices. Article 19 of the Insurance Law (voiding terms that exclude core rights) is the main legal basis for challenging such clauses. 2. Substantive evaluation of disease definitions - Correlating clause descriptions with ICD classifications is crucial. Claims based on diseases not explicitly listed in the clause typically fail in court. 3. Proving causality in undisclosed claims - Where concealed conditions lack medical relevance to the insured disease, termination or denial of coverage is unjustified. Insureds' rights protection path: - First, demand a written denial notice and clause justification from the insurer (oral denials must be documented). - Second, organize medical evidence - pathology reports, diagnosis certificates, disease classification codes (ICD codes on case files directly correspond to clause definitions), and treatment protocol/guidelines comparisons. - Third, choose litigation or regulatory channels - parallel complaints to regulators and lawsuits. Evidential burden: clause disputes + clause invalidation + unfavorable interpretation. Insurance company advice: - Standard treatment restrictions must align with medical norms. - Medical compliance in clause design and claims processing is essential to mitigate disputes. The establishment of the Beijing Financial Court centralizes professional adjudication of financial and insurance disputes, unifying critical illness claim adjudication standards. Patient success hinges on honest disclosure of health information and thorough understanding of clause provisions.

IV. Practical suggestions and legal basis

The first step is written refusal of compensation: requiring the issuance of a written notice and the provision of clause basis; the second step is medical organization: a complete set of evidence chains for pathology, ICD coding, and treatment guidelines; the third step is three-tier claims: clause disputes, invalidity of standard clauses, and unfavorable interpretation progressively; the fourth step is dual-track advancement: regulatory complaints and litigation proceed in parallel. Main legal basis: Article 17, Article 19 (invalidity of standard clauses), and Article 30 (unfavorable interpretation) of the Insurance Law of the People's Republic of China (amended in 2015); the Guidelines for the Use of Disease Definitions in Major Disease Insurance (2020 Revised Edition); Interpretations (II) and (III) of the Supreme People's Court on Several Issues Concerning the Application of the Insurance Law; specific application shall be subject to the currently effective regulations.

5. Henglue Law Firm's Advice

The key to disputes over critical illness claims is the "medical standard": treatment methods are not restricted by clauses, disease definitions are aligned with ICD codes, and causality prevents reopening old cases—three lines of defense ensure that the precedent of the 400,000 yuan case holds. The patience to read the clauses when applying for insurance is the foundation for avoiding disputes during claims processing. For disputes involving critical illness insurance and insurance claims, you can seek assistance through the following channels:\nFinancial capital and cross-border transactions involving foreign entitiesFor the overall solution of the service, if you want to refer to the extended issues involving personal health damage, you can check it outPersonal injury and medical disputesFor reference, you can check the section related to compensation executionCreditor's rights and debts, and enforcement casesThe modules can be combined to cover aspects such as insurance policy structure and family protection planningSpecialised legal servicesPlate consultation.

VI. Frequently Asked Questions

Q1: Can the insurance company compensate for illnesses that are not mentioned in the contract terms?

It's acceptable to classify diseases as substantially homogeneous according to the ICD medical classification, and the disease code is the core evidence.

Q2: Will the insurer refuse to pay the claim if the patient fails to follow the prescribed treatment plan?

The standard clauses that limit treatment methods are generally not supported, and the right to make reasonable medical choices is protected.

Q3: How to distinguish between mild and severe cases?

According to the disease definition table and staging and classification in the terms, the medical evidence determines the classification.

Q4: What if the insurer only issues a verbal notice of refusal to pay the claim?

It is always required to make a written claim and keep the relevant evidence. An oral refusal to compensate will not affect the claim made in accordance with the contract.

Q5: Is it useful to file a complaint against the China Banking and Insurance Regulatory Commission?

It's useful. Regulatory pressure and litigation go hand in hand, and most disputes are resolved at the complaint stage.

The above answer is based on the judicial practice in the Beijing area. The judicial interpretation in other provinces and cities may vary. For specific cases, please refer to the local rules and evidence situation.

VII. Relevant public cases (for reference only, not handled by our firm)

The following cases are all sourced from the official websites of courts at all levels, judicial authorities, and authoritative media outlets, and are not related to the cases handled by our firm. They are provided solely for reference in understanding relevant adjudication rules and do not constitute opinions on specific cases.

[Case No.]The case number has not been made public.
[Trial Court]Beijing Financial Court (Final Appeal)
[Judicial Summary]A 6-year-old boy was diagnosed with Wilson's disease, but the insurance company denied his claim on the grounds that he "did not receive treatment with the chelating agents specified in the contract". The court's investigation confirmed that the choice of treatment method had no necessary connection with the severity of the disease. The court held that the insurance contract could not impose a claim condition by restricting the insured's right to choose a reasonable treatment plan. Where the standard clauses set unreasonable claim obstacles that violate general medical standards, they shall not be supported in accordance with Article 19 of the Insurance Law. In the final judgment, the insurance company was ordered to pay the insurance compensation of 400,000 yuan and waive the subsequent premiums.
[Source]The Beijing Financial Court announced (as reported by CCTV News) that the trial of the case involving the illegal fund-raising of a certain company will begin on April 20, 2026.

[Case Number]The case number has not been made public.
[Trial Court]The People's Court of Pingjiang County, Hunan Province
[Judicial Summary]Ms. Li was diagnosed with acute myeloid leukemia and applied for a critical illness insurance claim, but the insurance company denied the claim on the grounds that she "did not disclose her pregnancy-induced anemia during the application process". The court held that the insurance company failed to provide evidence to prove that she still suffered from moderate to severe anemia at the time of application and the causal relationship between the anemia and the leukemia, so the termination of the contract was invalid. Moreover, according to the ICD-10 and ICD-O-3 medical classification standards, acute myeloid leukemia falls under the coverage of "malignant tumors - severe", and the court awarded her 99,874.72 yuan in critical illness insurance compensation.
[Source]China Court Online, August 2026 (2026-08)

If you are currently facing similar problems, it is recommended that you consult a professional lawyer as soon as possible with the relevant evidence, to avoid missing the statutory time limit. →Financial capital legal services·Beijing Henglu Law Firm

Disclaimer: This article is compiled based on the current effective laws and regulations and public adjudication rules, and is for general reference only. It does not constitute a formal legal opinion on specific cases. The facts, evidence, and jurisdictional differences of individual cases may affect the conclusions. In the event of a dispute, please consult a practicing lawyer in a timely manner.